Search
Now showing items 1-5 of 5
Biomarkers for Dementia and Mild Cognitive Impairment in Parkinson’s Disease
(Movement Disorders, 2016)
Cognitive decline is one of the most frequent and disabling nonmotor features of Parkinson's disease. Around 30% of patients with Parkinson's disease experience mild cognitive impairment, a well-established risk factor for ...
Stimulation sites in the subthalamic nucleus and clinical improvement in Parkinson's disease: a new approach for active contact localization
(Journal of Neurosurgery, 2016)
OBJECTIVE
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is widely used in patients with Parkinson's disease (PD). However, which target area of this region results in the highest antiparkinsonian efficacy ...
Abnormal pattern of brain glucose metabolism in Parkinson’s disease: replication in three European cohorts
(European Journal of Nuclear Medicine and Molecular Imaging, 2020)
Rationale
In Parkinson’s disease (PD), spatial covariance analysis of 18F-FDG PET data has consistently revealed a characteristic PD-related brain pattern (PDRP). By quantifying PDRP expression on a scan-by-scan basis, ...
Functional correlates of response inhibition in impulse control disorders in Parkinson’s disease
(NeuroImage: Clinical, 2021)
Impulse control disorder is a prevalent side-effect of Parkinson’s disease (PD) medication, with a strong negative
impact on the quality of life of those affected. Although impulsivity has classically been associated with ...
Interactions between functional networks in Parkinson's disease mild cognitive impairment
(NATURE, 2023)
The study of mild cognitive impairment (MCI) is critical to understand the underlying processes of cognitive decline in Parkinson’s disease (PD). Functional connectivity (FC) disruptions in PD-MCI patients have been observed ...